0 false false false false false false false false false false true false false false false false false No description of principal activity 2023-07-01 Sage Accounts Production Advanced 2023 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 12702329 2023-07-01 2024-06-30 12702329 2024-06-30 12702329 2023-06-30 12702329 2022-07-01 2023-06-30 12702329 2023-06-30 12702329 2022-06-30 12702329 bus:Director1 2023-07-01 2024-06-30 12702329 core:WithinOneYear 2024-06-30 12702329 core:WithinOneYear 2023-06-30 12702329 core:ShareCapital 2024-06-30 12702329 core:ShareCapital 2023-06-30 12702329 core:RetainedEarningsAccumulatedLosses 2024-06-30 12702329 core:RetainedEarningsAccumulatedLosses 2023-06-30 12702329 bus:SmallEntities 2023-07-01 2024-06-30 12702329 bus:AuditExempt-NoAccountantsReport 2023-07-01 2024-06-30 12702329 bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 12702329 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 12702329 bus:FullAccounts 2023-07-01 2024-06-30
COMPANY REGISTRATION NUMBER: 12702329
LVJPHARMA LTD
FILLETED UNAUDITED FINANCIAL STATEMENTS
30 June 2024
LVJPHARMA LTD
STATEMENT OF FINANCIAL POSITION
30 June 2024
2024
2023
Note
£
£
£
Current assets
Debtors
5
8,499
Cash at bank and in hand
9,182
1,747
-------
---------
9,182
10,246
Creditors: amounts falling due within one year
6
10,886
10,199
---------
---------
Net current (liabilities)/assets
( 1,704)
47
-------
----
Total assets less current liabilities
( 1,704)
47
-------
----
Net (liabilities)/assets
( 1,704)
47
-------
----
Capital and reserves
Called up share capital
100
100
Profit and loss account
( 1,804)
( 53)
-------
----
Shareholders (deficit)/funds
( 1,704)
47
-------
----
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
LVJPHARMA LTD
STATEMENT OF FINANCIAL POSITION (continued)
30 June 2024
These financial statements were approved by the board of directors and authorised for issue on 20 February 2025 , and are signed on behalf of the board by:
L Johnson
Director
Company registration number: 12702329
LVJPHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 168 Church Road, Hove, BN3 2DL.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.
4. Employee numbers
The average number of persons employed by the company during the year amounted to Nil (2023: 1 ).
5. Debtors
2024
2023
£
£
Other debtors
8,499
----
-------
6. Creditors: amounts falling due within one year
2024
2023
£
£
Other creditors
10,886
10,199
---------
---------
7. Director's advances, credits and guarantees
Included within creditors falling due in less then one year are directors' loans totaling £10,166 (2023: £9,479). These loans are interest free and repayable on demand.